Çilli A.Sayiner A.Çelenk B.Şakar Coşkun A.Kilinç O.Hazar A.Aktaş Samur A.Taşbakan S.Waterer G.W.Havlucu Y.Kiliç Ö.Tokgöz F.Bilge U.2024-07-222024-07-22201813000144http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15072Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a β-lactam, β-lactam and macrolide combination, or a fluoroquinolone. Materials and methods: This prospective cohort study was performed using standardized web-based database sheets from January 2009 to September 2013 in nine tertiary care hospitals in Turkey. Results: Six hundred and twenty-one consecutive patients were enrolled. A pathogen was identified in 78 (12.6%) patients. The most frequently isolated bacteria were S. pneumoniae (21.8%) and P. aeruginosa (19.2%). The clinical cure rate and length of stay were not different among patients treated with β-lactam, β-lactam and macrolide combination, and fluoroquinolone. Forty-seven patients (9.2%) died during the hospitalization period. There was no difference in survival among the three treatment groups. Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between β-lactam, β-lactam and macrolide combination, and fluoroquinolone regimens. © TÜBİTAK.EnglishAll Open Access; Bronze Open AccessAgedAged, 80 and overAnti-Bacterial Agentsbeta-LactamsCommunity-Acquired InfectionsDrug Therapy, CombinationFemaleFluoroquinolonesHospital DepartmentsHospital MortalityHospitalsHumansLength of StayMacrolidesMaleMiddle AgedPneumoniaProspective StudiesPseudomonas aeruginosaStreptococcus pneumoniaeTreatment OutcomeTurkeyalbuminbeta lactam antibioticbeta lactamase inhibitorceftriaxoneclarithromycinlevofloxacinmacrolidemoxifloxacinquinoline derived antiinfective agentantiinfective agentbeta lactammacrolidequinolone derivativeadultageagedantibiotic resistanceantibiotic therapyArticlecerebrovascular accidentchronic kidney failurechronic obstructive lung diseaseclinical trialcohort analysiscommunity acquired pneumoniaCURB-65 scorediabetes mellitusdrug treatment failureeosinophil countEscherichia colifollow upHaemophilus influenzaehospital mortalityhumanlength of staylung cancermajor clinical studymalemulticenter studyobservational studyoxygen tensionPneumonia Severity Indexprospective studyStaphylococcus aureusthorax radiographytreatment outcomecombination drug therapycommunity acquired infectionepidemiologyfemalegrowth, development and aginghospitalhospital departmentlength of staymicrobiologymiddle agedmortalitypneumoniaPseudomonas aeruginosaStreptococcus pneumoniaeturkey (bird)very elderlyArticle10.3906/sag-1709-144